Balyasny Asset Management
PGNX

Balyasny Asset Management’s Progenics Pharmaceuticals Inc PGNX Stock Holding History

Balyasny Asset Management’s Portfolio PGNX Stock Details PGNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-31,468
Closed -$197K – 1926
2018
Q3 		$197K Buy
+31,468
New +$242K ﹤0.01% 1586
2016
Q3 		– Sell
-24,437
Closed -$103K – 1373
2016
Q2 		$103K Buy
24,437
+2,706
+12% +$13.1K ﹤0.01% 1096
2016
Q1 		$95K Buy
+21,731
New +$96.8K ﹤0.01% 1204

Other funds holding PGNX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
CTA
Carillon Tower Advisers St. Petersburg, Florida $16.4B AUM 64.75% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return

Balyasny Asset Management's PGNX Position: Q4 2018 in Review

Balyasny Asset Management sold out of Progenics Pharmaceuticals Inc (PGNX) in Q4 2018, closing a stake of 31,468 shares — an estimated $197K sold.

Balyasny Asset Management first reported a position in PGNX in Q1 2016 and held it in 3 quarters. The position peaked at $197K in Q3 2018. 150 funds tracked by Wall St. Rank hold PGNX as of Q4 2018.

  • Balyasny Asset Management reported no remaining Progenics Pharmaceuticals Inc position as of Q4 2018 after selling out during the quarter.
  • Balyasny Asset Management sold 31,468 Progenics Pharmaceuticals Inc shares in Q4 2018, an estimated $197K.
  • Balyasny Asset Management first reported a position in Progenics Pharmaceuticals Inc in Q1 2016 and held it in 3 quarters.
  • Balyasny Asset Management's Progenics Pharmaceuticals Inc position peaked at $197K in Q3 2018.
  • 150 funds tracked by Wall St. Rank held Progenics Pharmaceuticals Inc as of Q4 2018.

Based on Balyasny Asset Management's 13F filing for Q4 2018, filed 14 Feb 2019.